13 years of historical data (2012–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
PureTech Health plc trades at 8.4x earnings, 94% below its 5-year average of 139.6x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 65%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $405M | $498M | $779M | $908M | $1.1B | $1.6B | — | — | — | — | — |
| Enterprise Value | $147M | $240M | $613M | $805M | $647M | $1.3B | — | — | — | — | — |
| P/E Ratio → | 8.38 | 9.23 | — | — | — | 270.00 | — | — | — | — | — |
| P/S Ratio | 83.95 | 103.10 | 233.82 | 434.63 | 106.26 | 189.60 | — | — | — | — | — |
| P/B Ratio | 1.11 | 1.22 | 1.70 | 1.66 | 1.82 | 2.42 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 49.61 | 184.05 | 385.35 | 64.81 | 150.36 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | 7.08 | — | — | 33.23 | 22.38 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
PureTech Health plc earns an operating margin of -2818.9%. Operating margins have expanded from -9464.4% to -2818.9% over the past 3 years, signaling improving operational efficiency. ROE of 12.4% is modest.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 26.0% | 26.0% | -48.1% | -6546.2% | -1007.0% | 100.0% | -888.1% | -372.8% | -10828.5% | 64.6% | 93.7% |
| Operating Margin | -2818.9% | -2818.9% | -4390.4% | -9464.4% | -1506.0% | -1433.1% | -1558.5% | -635.4% | -17756.9% | -1668.4% | -371.7% |
| Net Profit Margin | 1108.3% | 1108.3% | -1972.9% | -2409.3% | -606.9% | 71.8% | 4847.4% | -266.7% | 4749.1% | -1101.2% | -335.5% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.4% | 12.4% | -13.1% | -8.9% | -9.8% | 0.9% | 103.0% | -37.8% | 39.5% | -38.0% | -26.5% |
| ROA | 8.3% | 8.3% | -9.4% | -6.1% | -6.3% | 0.6% | 60.9% | -11.2% | 9.7% | -15.6% | -14.2% |
| ROIC | -46.2% | -46.2% | -29.8% | -48.2% | -45.3% | -20.3% | -32.8% | -255.4% | -491.7% | -156.9% | -95.5% |
| ROCE | -22.6% | -22.6% | -23.4% | -29.8% | -19.7% | -14.8% | -27.7% | -86.0% | -143.7% | -56.7% | -29.0% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $281M exceeds total debt of $22M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.06 | 0.09 | 0.09 | 0.12 | 0.06 | 0.07 | 0.12 | 0.08 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | -0.36 | -0.19 | -0.71 | -0.50 | -0.14 | -0.63 | -1.02 | -0.61 | -0.79 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -13.56 | -13.56 | -10.84 | -50.04 | -31.88 | -40.57 | -33.01 | -7.03 | -11.30 | -10.86 | -10.03 |
Net cash position: cash ($281M) exceeds total debt ($22M)
Short-term solvency ratios and asset-utilisation metrics
PureTech Health plc's current ratio of 9.33x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.99x to 9.33x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.33 | 9.33 | 6.76 | 3.99 | 2.22 | 2.29 | 1.21 | 0.98 | 0.72 | 1.41 | 1.98 |
| Quick Ratio | 9.33 | 9.33 | 6.76 | 3.99 | 2.10 | 2.29 | 1.21 | 0.98 | 0.73 | 1.42 | 1.98 |
| Cash Ratio | 8.87 | 8.87 | 6.37 | 3.61 | 2.06 | 2.23 | 1.17 | 0.94 | 0.69 | 1.38 | 1.96 |
| Asset Turnover | — | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 |
| Inventory Turnover | 3.95 | — | — | — | 3.95 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 975.48 | 260.43 | 3904.45 | 131.27 | 128.61 | 97.76 | 29.61 | 1009.08 | 10.30 | 21.95 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
PureTech Health plc returns 26.5% to shareholders annually primarily through share buybacks. The earnings yield of 11.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | 0.0% | — | 0.3% | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 11.9% | 10.8% | — | — | — | 0.4% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 26.5% | 21.6% | 2.5% | 2.9% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 26.5% | 21.6% | 2.5% | 2.9% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $27M | $28M | $28M | $29M | $29M | $29M | $27M | $24M | $23M | $19M |
Compare PRTC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PRTCYou | $405M | 8.4 | — | — | 26.0% | -2818.9% | 12.4% | -46.2% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PRTC stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonPureTech Health plc's current P/E ratio is 8.4x. The historical average is 9.2x.
PureTech Health plc's return on equity (ROE) is 12.4%. The historical average is -4.0%.
Based on historical data, PureTech Health plc is trading at a P/E of 8.4x. Compare with industry peers and growth rates for a complete picture.
PureTech Health plc has 26.0% gross margin and -2818.9% operating margin.